Relating to wholesale importation of prescription drugs
House Bill 5144 would create a new Wholesale Prescription Drug Importation Program within the West Virginia Department of Health and Human Resources. The program is intended to allow the state, or a contractor acting on its behalf, to import certain prescription drugs from Canada for sale in West Virginia, but only if the federal Department of Health and Human Services approves and certifies the program under federal law. The bill sets out detailed design requirements, including use of licensed wholesalers and distributors, reliance on Canadian suppliers regulated under Canadian law, compliance with FDA safety standards, and a focus on drugs expected to produce substantial cost savings for consumers.
The bill also requires the department to develop rules, seek federal approval, and implement the program within a specified timeline after certification. It directs the department to create a public website with drug prices, establish consumer and stakeholder outreach, provide a hotline, and maintain an audit work plan. In addition, the department must report annually to the Legislative Oversight Commission on Health and Human Resources Accountability on participation, drugs imported, prescriptions dispensed, estimated savings, and audit findings.
If enacted, the bill would add a new article to the West Virginia Code authorizing a state-run prescription drug importation framework and assigning implementation duties to the Department of Health and Human Resources. It would not take effect as an importation program unless federal approval is obtained, but it would create the legal structure for the state to become or contract with a licensed drug wholesaler, work with Canadian suppliers, and manage the program under federal importation rules. The bill would also impose ongoing reporting obligations and potentially affect pharmacies, health insurers, employers, providers, and consumers by creating a new channel for lower-cost prescription drugs.
The bill’s overall tone is supportive of lowering drug costs and expanding access through a state-administered importation program. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate or opposition in the supplied materials. The bill text itself emphasizes consumer savings, safety, and regulatory compliance, suggesting a policy goal that is generally favorable to cost reduction in prescription drug purchasing.
The main points of potential contention are the reliance on federal approval, the use of Canadian drug suppliers, and the practical and legal complexity of setting up a compliant importation system. Stakeholders such as pharmacies, health insurers, employers, and health care providers may have differing views on whether the program would actually produce meaningful savings, how it would be financed, and whether safety and supply-chain requirements can be met. Another possible issue is the administrative burden on the Department of Health and Human Resources, which would need to secure certification, establish contracts, create an audit system, and manage public reporting before the program can operate.